Wojtowicz Malgorzata E, Dunn Barbara K, Umar Asad
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Semin Oncol. 2016 Feb;43(1):161-172. doi: 10.1053/j.seminoncol.2015.11.001. Epub 2015 Nov 14.
The potential of the immune system to recognize and reject tumors has been investigated for more than a century. However, only recently impressive breakthroughs in cancer immunotherapy have been seen with the use of checkpoint inhibitors. The experience with various immune-based strategies in the treatment of late cancer highlighted the importance of negative impact advanced disease has on immunity. Consequently, use of immune modulation for cancer prevention rather than therapy has gained considerable attention, with many promising results seen already in preclinical and early clinical studies. Although not without challenges, these results provide much excitement and optimism that successful cancer immunoprevention could be within our reach. In this review we will discuss the current state of predominantly primary and secondary cancer immunoprevention, relevant research, potential barriers, and future directions.
免疫系统识别和排斥肿瘤的潜力已被研究了一个多世纪。然而,直到最近,使用检查点抑制剂才在癌症免疫治疗方面取得了令人瞩目的突破。在晚期癌症治疗中使用各种基于免疫的策略的经验凸显了晚期疾病对免疫产生负面影响的重要性。因此,利用免疫调节进行癌症预防而非治疗受到了广泛关注,在临床前和早期临床研究中已经取得了许多有前景的结果。尽管并非没有挑战,但这些结果带来了极大的兴奋和乐观情绪,即成功的癌症免疫预防可能指日可待。在这篇综述中,我们将讨论主要的原发性和继发性癌症免疫预防的现状、相关研究、潜在障碍以及未来方向。